CA3077187A1 - Pd1-specific chimeric antigen receptor as an immunotherapy - Google Patents

Info

Publication number

CA3077187A1

CA3077187A1 CA3077187A CA3077187A CA3077187A1 CA 3077187 A1 CA3077187 A1 CA 3077187A1 CA 3077187 A CA3077187 A CA 3077187A CA 3077187 A CA3077187 A CA 3077187A CA 3077187 A1 CA3077187 A1 CA 3077187A1

Authority

CA

Canada

Prior art keywords

cells

domain

cell

car

chpd1

Prior art date

2017-09-26

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 108010019670 Chimeric Antigen Receptors Proteins 0.000 title claims abstract description 69
• 238000009169 immunotherapy Methods 0.000 title description 5
• 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 233
• 210000004027 cell Anatomy 0.000 claims abstract description 117
• 206010028980 Neoplasm Diseases 0.000 claims abstract description 91
• 239000000203 mixture Substances 0.000 claims abstract description 28
• 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims abstract description 27
• 238000000034 method Methods 0.000 claims abstract description 21
• 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims abstract description 20
• 238000012546 transfer Methods 0.000 claims abstract description 13
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 40
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 36
• 229920001184 polypeptide Polymers 0.000 claims description 33
• 201000011510 cancer Diseases 0.000 claims description 32
• 108090000623 proteins and genes Proteins 0.000 claims description 27
• 239000013598 vector Substances 0.000 claims description 26
• 101150090209 HCST gene Proteins 0.000 claims description 25
• 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 25
• 206010025323 Lymphomas Diseases 0.000 claims description 23
• 230000001086 cytosolic effect Effects 0.000 claims description 23
• 102000004169 proteins and genes Human genes 0.000 claims description 21
• 230000011664 signaling Effects 0.000 claims description 19
• 108010074708 B7-H1 Antigen Proteins 0.000 claims description 17
• 239000003795 chemical substances by application Substances 0.000 claims description 12
• 230000027455 binding Effects 0.000 claims description 8
• 230000003439 radiotherapeutic effect Effects 0.000 claims description 8
• 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 claims description 7
• 206010033128 Ovarian cancer Diseases 0.000 claims description 5
• 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
• 230000000973 chemotherapeutic effect Effects 0.000 claims description 5
• 206010006187 Breast cancer Diseases 0.000 claims description 4
• 208000026310 Breast neoplasm Diseases 0.000 claims description 4
• 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
• 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
• 239000003937 drug carrier Substances 0.000 claims description 4
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
• 201000001441 melanoma Diseases 0.000 claims description 4
• 201000000050 myeloid neoplasm Diseases 0.000 claims description 4
• 201000002528 pancreatic cancer Diseases 0.000 claims description 4
• 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
• 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 abstract description 2
• 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 abstract description 2
• 241000699670 Mus sp. Species 0.000 description 52
• 102000004127 Cytokines Human genes 0.000 description 43
• 108090000695 Cytokines Proteins 0.000 description 43
• 108020003175 receptors Proteins 0.000 description 42
• 102000005962 receptors Human genes 0.000 description 42
• 102100040678 Programmed cell death protein 1 Human genes 0.000 description 36
• 230000014509 gene expression Effects 0.000 description 29
• 230000004083 survival effect Effects 0.000 description 25
• 238000011282 treatment Methods 0.000 description 25
• 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 24
• 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 24
• 230000028327 secretion Effects 0.000 description 24
• 239000012636 effector Substances 0.000 description 22
• 230000000770 proinflammatory effect Effects 0.000 description 22
• 210000004881 tumor cell Anatomy 0.000 description 22
• 230000000259 anti-tumor effect Effects 0.000 description 21
• 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 20
• 235000018102 proteins Nutrition 0.000 description 19
• 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 18
• 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 description 18
• 238000002347 injection Methods 0.000 description 18
• 239000007924 injection Substances 0.000 description 18
• 101710089372 Programmed cell death protein 1 Proteins 0.000 description 16
• 239000003446 ligand Substances 0.000 description 16
• 241001529936 Murinae Species 0.000 description 14
• 230000004913 activation Effects 0.000 description 14
• 235000001014 amino acid Nutrition 0.000 description 14
• 230000003110 anti-inflammatory effect Effects 0.000 description 13
• 238000001727 in vivo Methods 0.000 description 13
• -1 CD3s Proteins 0.000 description 12
• 150000001413 amino acids Chemical class 0.000 description 12
• 230000006870 function Effects 0.000 description 12
• 229940024606 amino acid Drugs 0.000 description 11
• 230000000694 effects Effects 0.000 description 11
• 239000000243 solution Substances 0.000 description 11
• 238000002560 therapeutic procedure Methods 0.000 description 11
• 230000004069 differentiation Effects 0.000 description 10
• 238000000684 flow cytometry Methods 0.000 description 10
• 210000001165 lymph node Anatomy 0.000 description 10
• 210000000952 spleen Anatomy 0.000 description 10
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
• 238000002474 experimental method Methods 0.000 description 9
• 230000002829 reductive effect Effects 0.000 description 9
• 230000001225 therapeutic effect Effects 0.000 description 9
• 108010002350 Interleukin-2 Proteins 0.000 description 8
• 102000000588 Interleukin-2 Human genes 0.000 description 8
• 108091033319 polynucleotide Proteins 0.000 description 8
• 102000040430 polynucleotide Human genes 0.000 description 8
• 239000002157 polynucleotide Substances 0.000 description 8
• 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 7
• 238000002659 cell therapy Methods 0.000 description 7
• 206010052015 cytokine release syndrome Diseases 0.000 description 7
• 238000009472 formulation Methods 0.000 description 7
• 230000006698 induction Effects 0.000 description 7
• 230000001177 retroviral effect Effects 0.000 description 7
• 239000006228 supernatant Substances 0.000 description 7
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
• 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 6
• 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 6
• 125000003275 alpha amino acid group Chemical group 0.000 description 6
• 150000001875 compounds Chemical class 0.000 description 6
• 108091008034 costimulatory receptors Proteins 0.000 description 6
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
• 239000006185 dispersion Substances 0.000 description 6
• 239000013604 expression vector Substances 0.000 description 6
• 230000002401 inhibitory effect Effects 0.000 description 6
• 239000002953 phosphate buffered saline Substances 0.000 description 6
• 238000012360 testing method Methods 0.000 description 6
• 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 5
• 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 5
• 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 5
• 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 5
• 241001465754 Metazoa Species 0.000 description 5
• 108091028043 Nucleic acid sequence Proteins 0.000 description 5
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
• 230000005867 T cell response Effects 0.000 description 5
• 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 5
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
• 102100040247 Tumor necrosis factor Human genes 0.000 description 5
• 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 5
• 239000013543 active substance Substances 0.000 description 5
• 230000002411 adverse Effects 0.000 description 5
• 230000005809 anti-tumor immunity Effects 0.000 description 5
• 230000006037 cell lysis Effects 0.000 description 5
• 230000009089 cytolysis Effects 0.000 description 5
• 230000003247 decreasing effect Effects 0.000 description 5
• 201000010099 disease Diseases 0.000 description 5
• 230000007774 longterm Effects 0.000 description 5
• 238000002360 preparation method Methods 0.000 description 5
• 150000003839 salts Chemical class 0.000 description 5
• 102000019034 Chemokines Human genes 0.000 description 4
• 108010012236 Chemokines Proteins 0.000 description 4
• 108020004414 DNA Proteins 0.000 description 4
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
• 108091008874 T cell receptors Proteins 0.000 description 4
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 4
• 241000700605 Viruses Species 0.000 description 4
• 239000002246 antineoplastic agent Substances 0.000 description 4
• 231100000135 cytotoxicity Toxicity 0.000 description 4
• 230000003013 cytotoxicity Effects 0.000 description 4
• 208000035475 disorder Diseases 0.000 description 4
• 230000012010 growth Effects 0.000 description 4
• 210000002865 immune cell Anatomy 0.000 description 4
• 238000001802 infusion Methods 0.000 description 4
• 239000003112 inhibitor Substances 0.000 description 4
• 230000005764 inhibitory process Effects 0.000 description 4
• 230000000670 limiting effect Effects 0.000 description 4
• 239000007788 liquid Substances 0.000 description 4
• 238000010172 mouse model Methods 0.000 description 4
• 239000013612 plasmid Substances 0.000 description 4
• 230000009467 reduction Effects 0.000 description 4
• 238000003757 reverse transcription PCR Methods 0.000 description 4
• 239000011780 sodium chloride Substances 0.000 description 4
• 230000000638 stimulation Effects 0.000 description 4
• 238000006467 substitution reaction Methods 0.000 description 4
• 210000001519 tissue Anatomy 0.000 description 4
• 230000002463 transducing effect Effects 0.000 description 4
• 241000701022 Cytomegalovirus Species 0.000 description 3
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
• 238000002965 ELISA Methods 0.000 description 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
• 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 3
• 102000013691 Interleukin-17 Human genes 0.000 description 3
• 108090001005 Interleukin-6 Proteins 0.000 description 3
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
• 241000699666 Mus <mouse, genus> Species 0.000 description 3
• 239000012980 RPMI-1640 medium Substances 0.000 description 3
• 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 3
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
• 238000004458 analytical method Methods 0.000 description 3
• 239000002111 antiemetic agent Substances 0.000 description 3
• 229940125683 antiemetic agent Drugs 0.000 description 3
• 239000000427 antigen Substances 0.000 description 3
• 102000036639 antigens Human genes 0.000 description 3
• 108091007433 antigens Proteins 0.000 description 3
• 239000007864 aqueous solution Substances 0.000 description 3
• 238000003556 assay Methods 0.000 description 3
• 239000002458 cell surface marker Substances 0.000 description 3
• 239000002299 complementary DNA Substances 0.000 description 3
• 230000001419 dependent effect Effects 0.000 description 3
• 239000012634 fragment Substances 0.000 description 3
• 239000004615 ingredient Substances 0.000 description 3
• 108091008042 inhibitory receptors Proteins 0.000 description 3
• 230000003993 interaction Effects 0.000 description 3
• 230000003834 intracellular effect Effects 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 244000005700 microbiome Species 0.000 description 3
• 239000003612 morphinomimetic agent Substances 0.000 description 3
• 238000011275 oncology therapy Methods 0.000 description 3
• 210000000056 organ Anatomy 0.000 description 3
• 230000002688 persistence Effects 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• 230000035755 proliferation Effects 0.000 description 3
• 238000001959 radiotherapy Methods 0.000 description 3
• 230000001105 regulatory effect Effects 0.000 description 3
• 239000007787 solid Substances 0.000 description 3
• 239000002904 solvent Substances 0.000 description 3
• 238000007619 statistical method Methods 0.000 description 3
• 208000024891 symptom Diseases 0.000 description 3
• 230000008685 targeting Effects 0.000 description 3
• 230000002476 tumorcidal effect Effects 0.000 description 3
• 239000004474 valine Substances 0.000 description 3
• 239000013603 viral vector Substances 0.000 description 3
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
• FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 2
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
• ULTTYPMRMMDONC-UHFFFAOYSA-N 5-[(2,5-dihydroxyphenyl)methyl-[(2-hydroxyphenyl)methyl]amino]-2-hydroxybenzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(N(CC=2C(=CC=CC=2)O)CC=2C(=CC=C(O)C=2)O)=C1 ULTTYPMRMMDONC-UHFFFAOYSA-N 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 102100021631 B-cell lymphoma 6 protein Human genes 0.000 description 2
• 102100038080 B-cell receptor CD22 Human genes 0.000 description 2
• 108010006654 Bleomycin Proteins 0.000 description 2
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
• 108010092160 Dactinomycin Proteins 0.000 description 2
• 241000702421 Dependoparvovirus Species 0.000 description 2
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
• 101000971234 Homo sapiens B-cell lymphoma 6 protein Proteins 0.000 description 2
• 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 2
• 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 2
• 101000971533 Homo sapiens Killer cell lectin-like receptor subfamily G member 1 Proteins 0.000 description 2
• 101000713602 Homo sapiens T-box transcription factor TBX21 Proteins 0.000 description 2
• 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 description 2
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
• 206010061218 Inflammation Diseases 0.000 description 2
• 108010002616 Interleukin-5 Proteins 0.000 description 2
• 102100021457 Killer cell lectin-like receptor subfamily G member 1 Human genes 0.000 description 2
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
• 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
• TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• 206010027476 Metastases Diseases 0.000 description 2
• 101100445364 Mus musculus Eomes gene Proteins 0.000 description 2
• 102000015636 Oligopeptides Human genes 0.000 description 2
• 108010038807 Oligopeptides Proteins 0.000 description 2
• 102100024894 PR domain zinc finger protein 1 Human genes 0.000 description 2
• 102000002508 Peptide Elongation Factors Human genes 0.000 description 2
• 108010068204 Peptide Elongation Factors Proteins 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• 102100028251 Phosphoglycerate kinase 1 Human genes 0.000 description 2
• 101710139464 Phosphoglycerate kinase 1 Proteins 0.000 description 2
• 108010004729 Phycoerythrin Proteins 0.000 description 2
• 102100037935 Polyubiquitin-C Human genes 0.000 description 2
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
• 108091007744 Programmed cell death receptors Proteins 0.000 description 2
• 108091008611 Protein Kinase B Proteins 0.000 description 2
• 230000006044 T cell activation Effects 0.000 description 2
• 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 description 2
• 229940123237 Taxane Drugs 0.000 description 2
• 108091023040 Transcription factor Proteins 0.000 description 2
• 102000040945 Transcription factor Human genes 0.000 description 2
• 206010054094 Tumour necrosis Diseases 0.000 description 2
• 108010056354 Ubiquitin C Proteins 0.000 description 2
• 101100445365 Xenopus laevis eomes gene Proteins 0.000 description 2
• 238000010521 absorption reaction Methods 0.000 description 2
• RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 230000003213 activating effect Effects 0.000 description 2
• 239000004480 active ingredient Substances 0.000 description 2
• 239000000362 adenosine triphosphatase inhibitor Substances 0.000 description 2
• 108010004469 allophycocyanin Proteins 0.000 description 2
• 125000000539 amino acid group Chemical group 0.000 description 2
• 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 2
• 239000002249 anxiolytic agent Substances 0.000 description 2
• 239000012736 aqueous medium Substances 0.000 description 2
• 230000009286 beneficial effect Effects 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• 229960001561 bleomycin Drugs 0.000 description 2
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
• 230000000903 blocking effect Effects 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 230000024245 cell differentiation Effects 0.000 description 2
• 210000000170 cell membrane Anatomy 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• 238000002512 chemotherapy Methods 0.000 description 2
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
• 230000034994 death Effects 0.000 description 2
• 230000007423 decrease Effects 0.000 description 2
• 230000007120 differential activation Effects 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• 239000002612 dispersion medium Substances 0.000 description 2
• 229960004679 doxorubicin Drugs 0.000 description 2
• 229940079593 drug Drugs 0.000 description 2
• 239000003814 drug Substances 0.000 description 2
• 210000003162 effector t lymphocyte Anatomy 0.000 description 2
• 230000002708 enhancing effect Effects 0.000 description 2
• 229960002949 fluorouracil Drugs 0.000 description 2
• 229960003727 granisetron Drugs 0.000 description 2
• MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 2
• 230000036541 health Effects 0.000 description 2
• 238000001794 hormone therapy Methods 0.000 description 2
• 230000002209 hydrophobic effect Effects 0.000 description 2
• 230000003463 hyperproliferative effect Effects 0.000 description 2
• 230000028993 immune response Effects 0.000 description 2
• 230000004957 immunoregulator effect Effects 0.000 description 2
• 230000005917 in vivo anti-tumor Effects 0.000 description 2
• 238000011534 incubation Methods 0.000 description 2
• CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
• 230000001939 inductive effect Effects 0.000 description 2
• 230000002757 inflammatory effect Effects 0.000 description 2
• 230000004054 inflammatory process Effects 0.000 description 2
• 238000007912 intraperitoneal administration Methods 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• 238000002843 lactate dehydrogenase assay Methods 0.000 description 2
• 238000004519 manufacturing process Methods 0.000 description 2
• 230000007246 mechanism Effects 0.000 description 2
• 239000002609 medium Substances 0.000 description 2
• 239000012528 membrane Substances 0.000 description 2
• 210000003071 memory t lymphocyte Anatomy 0.000 description 2
• 230000009401 metastasis Effects 0.000 description 2
• 230000004048 modification Effects 0.000 description 2
• 238000012986 modification Methods 0.000 description 2
• BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
• 210000000822 natural killer cell Anatomy 0.000 description 2
• 230000001613 neoplastic effect Effects 0.000 description 2
• 229940121367 non-opioid analgesics Drugs 0.000 description 2
• 150000007523 nucleic acids Chemical class 0.000 description 2
• 239000003921 oil Substances 0.000 description 2
• 235000019198 oils Nutrition 0.000 description 2
• 229960005343 ondansetron Drugs 0.000 description 2
• 238000007911 parenteral administration Methods 0.000 description 2
• 230000001575 pathological effect Effects 0.000 description 2
• 239000008194 pharmaceutical composition Substances 0.000 description 2
• 239000002504 physiological saline solution Substances 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 230000008569 process Effects 0.000 description 2
• 230000010076 replication Effects 0.000 description 2
• 230000003248 secreting effect Effects 0.000 description 2
• 230000019491 signal transduction Effects 0.000 description 2
• 239000001488 sodium phosphate Substances 0.000 description 2
• 210000004988 splenocyte Anatomy 0.000 description 2
• 238000003860 storage Methods 0.000 description 2
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 239000004094 surface-active agent Substances 0.000 description 2
• WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
• GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
• 230000003827 upregulation Effects 0.000 description 2
• 239000003981 vehicle Substances 0.000 description 2
• DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
• YQYVFVRQLZMJKJ-JBBXEZCESA-N (+)-cyclazocine Chemical compound C([C@@]1(C)C2=CC(O)=CC=C2C[C@@H]2[C@@H]1C)CN2CC1CC1 YQYVFVRQLZMJKJ-JBBXEZCESA-N 0.000 description 1
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
• RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
• DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
• FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
• BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 description 1
• 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
• VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
• COTYIKUDNNMSDT-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-(1,3-dimethyl-2,6-dioxopurin-7-yl)acetic acid Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CC(O)=O)C=N2.O=C1N(C)C(=O)N(C)C2=C1N(CC(O)=O)C=N2.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 COTYIKUDNNMSDT-UHFFFAOYSA-N 0.000 description 1
• NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
• AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
• GIYAQDDTCWHPPL-UHFFFAOYSA-N 4-amino-5-bromo-N-[2-(diethylamino)ethyl]-2-methoxybenzamide Chemical compound CCN(CC)CCNC(=O)C1=CC(Br)=C(N)C=C1OC GIYAQDDTCWHPPL-UHFFFAOYSA-N 0.000 description 1
• BVPWJMCABCPUQY-UHFFFAOYSA-N 4-amino-5-chloro-2-methoxy-N-[1-(phenylmethyl)-4-piperidinyl]benzamide Chemical compound COC1=CC(N)=C(Cl)C=C1C(=O)NC1CCN(CC=2C=CC=CC=2)CC1 BVPWJMCABCPUQY-UHFFFAOYSA-N 0.000 description 1
• USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
• KSEYRUGYKHXGFW-UHFFFAOYSA-N 6-methoxy-N-[(1-prop-2-enyl-2-pyrrolidinyl)methyl]-2H-benzotriazole-5-carboxamide Chemical compound COC1=CC2=NNN=C2C=C1C(=O)NCC1CCCN1CC=C KSEYRUGYKHXGFW-UHFFFAOYSA-N 0.000 description 1
• VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
• NFLLKCVHYJRNRH-UHFFFAOYSA-N 8-chloro-1,3-dimethyl-7H-purine-2,6-dione 2-(diphenylmethyl)oxy-N,N-dimethylethanamine Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC(Cl)=N2.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 NFLLKCVHYJRNRH-UHFFFAOYSA-N 0.000 description 1
• 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
• 241000251468 Actinopterygii Species 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
• 206010061424 Anal cancer Diseases 0.000 description 1
• 108010083359 Antigen Receptors Proteins 0.000 description 1
• 102000006306 Antigen Receptors Human genes 0.000 description 1
• 208000007860 Anus Neoplasms Diseases 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• 108010024976 Asparaginase Proteins 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• 206010005949 Bone cancer Diseases 0.000 description 1
• 208000018084 Bone neoplasm Diseases 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
• 108700031361 Brachyury Proteins 0.000 description 1
• 208000003174 Brain Neoplasms Diseases 0.000 description 1
• 238000011740 C57BL/6 mouse Methods 0.000 description 1
• 238000011357 CAR T-cell therapy Methods 0.000 description 1
• 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
• 102100037904 CD9 antigen Human genes 0.000 description 1
• 102000004612 Calcium-Transporting ATPases Human genes 0.000 description 1
• 108010017954 Calcium-Transporting ATPases Proteins 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
• GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 102100025466 Carcinoembryonic antigen-related cell adhesion molecule 3 Human genes 0.000 description 1
• DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
• 229940123587 Cell cycle inhibitor Drugs 0.000 description 1
• 206010008342 Cervix carcinoma Diseases 0.000 description 1
• 206010009944 Colon cancer Diseases 0.000 description 1
• 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
• 208000035473 Communicable disease Diseases 0.000 description 1
• 108010062580 Concanavalin A Proteins 0.000 description 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
• 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
• 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
• 206010013975 Dyspnoeas Diseases 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• 102000004190 Enzymes Human genes 0.000 description 1
• 108090000790 Enzymes Proteins 0.000 description 1
• HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 1
• 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
• 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• 241000282575 Gorilla Species 0.000 description 1
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
• 102000001398 Granzyme Human genes 0.000 description 1
• 108060005986 Granzyme Proteins 0.000 description 1
• 239000007995 HEPES buffer Substances 0.000 description 1
• 206010066476 Haematological malignancy Diseases 0.000 description 1
• MCAHMSDENAOJFZ-UHFFFAOYSA-N Herbimycin A Natural products N1C(=O)C(C)=CC=CC(OC)C(OC(N)=O)C(C)=CC(C)C(OC)C(OC)CC(C)C(OC)C2=CC(=O)C=C1C2=O MCAHMSDENAOJFZ-UHFFFAOYSA-N 0.000 description 1
• GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
• 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
• 241000238631 Hexapoda Species 0.000 description 1
• 102100022132 High affinity immunoglobulin epsilon receptor subunit gamma Human genes 0.000 description 1
• 108091010847 High affinity immunoglobulin epsilon receptor subunit gamma Proteins 0.000 description 1
• 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
• 241001272567 Hominoidea Species 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 1
• 101000914337 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 3 Proteins 0.000 description 1
• 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
• 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 1
• 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
• 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
• 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
• 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 description 1
• 101000603882 Homo sapiens Nuclear receptor subfamily 1 group I member 3 Proteins 0.000 description 1
• 101000687344 Homo sapiens PR domain zinc finger protein 1 Proteins 0.000 description 1
• 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
• 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 description 1
• 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
• STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
• XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
• XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
• 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
• 102000005755 Intercellular Signaling Peptides and Proteins Human genes 0.000 description 1
• 108010070716 Intercellular Signaling Peptides and Proteins Proteins 0.000 description 1
• 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
• 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 1
• 208000008839 Kidney Neoplasms Diseases 0.000 description 1
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
• 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
• 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
• 241000713666 Lentivirus Species 0.000 description 1
• 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 1
• HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
• JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 description 1
• 102000003960 Ligases Human genes 0.000 description 1
• 108090000364 Ligases Proteins 0.000 description 1
• GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
• 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 1
• 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 1
• OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 1
• SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
• 229930192392 Mitomycin Natural products 0.000 description 1
• 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 1
• 101100268066 Mus musculus Zap70 gene Proteins 0.000 description 1
• 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
• IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 description 1
• WUKZPHOXUVCQOR-UHFFFAOYSA-N N-(1-azabicyclo[2.2.2]octan-3-yl)-6-chloro-4-methyl-3-oxo-1,4-benzoxazine-8-carboxamide Chemical compound C1N(CC2)CCC2C1NC(=O)C1=CC(Cl)=CC2=C1OCC(=O)N2C WUKZPHOXUVCQOR-UHFFFAOYSA-N 0.000 description 1
• STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
• WXNXCEHXYPACJF-ZETCQYMHSA-N N-acetyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(C)=O WXNXCEHXYPACJF-ZETCQYMHSA-N 0.000 description 1
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
• 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 description 1
• BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
• CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
• BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
• UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 1
• 229930012538 Paclitaxel Natural products 0.000 description 1
• 241000282577 Pan troglodytes Species 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 108010039918 Polylysine Proteins 0.000 description 1
• 108010009975 Positive Regulatory Domain I-Binding Factor 1 Proteins 0.000 description 1
• 206010060862 Prostate cancer Diseases 0.000 description 1
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
• 102000001253 Protein Kinase Human genes 0.000 description 1
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
• 102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 description 1
• LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
• 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 1
• 238000010802 RNA extraction kit Methods 0.000 description 1
• 238000011529 RT qPCR Methods 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
• ZTVQQQVZCWLTDF-UHFFFAOYSA-N Remifentanil Chemical compound C1CN(CCC(=O)OC)CCC1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 ZTVQQQVZCWLTDF-UHFFFAOYSA-N 0.000 description 1
• 206010038389 Renal cancer Diseases 0.000 description 1
• 108091027981 Response element Proteins 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 208000000453 Skin Neoplasms Diseases 0.000 description 1
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
• 241000713880 Spleen focus-forming virus Species 0.000 description 1
• 208000000277 Splenic Neoplasms Diseases 0.000 description 1
• 238000000692 Student's t-test Methods 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• 230000020385 T cell costimulation Effects 0.000 description 1
• 230000006052 T cell proliferation Effects 0.000 description 1
• 102100036840 T-box transcription factor TBX21 Human genes 0.000 description 1
• 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 description 1
• 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
• 108700012920 TNF Proteins 0.000 description 1
• 208000024313 Testicular Neoplasms Diseases 0.000 description 1
• 206010057644 Testis cancer Diseases 0.000 description 1
• 239000004098 Tetracycline Substances 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
• 238000010162 Tukey test Methods 0.000 description 1
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
• 229940122803 Vinca alkaloid Drugs 0.000 description 1
• JSZILQVIPPROJI-CEXWTWQISA-N [(2R,3R,11bS)-3-(diethylcarbamoyl)-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl] acetate Chemical compound C1CC2=CC(OC)=C(OC)C=C2[C@H]2N1C[C@@H](C(=O)N(CC)CC)[C@H](OC(C)=O)C2 JSZILQVIPPROJI-CEXWTWQISA-N 0.000 description 1
• UVAZQQHAVMNMHE-BBRMVZONSA-N [(3s,4s)-1,3-dimethyl-4-phenylpiperidin-4-yl] propanoate Chemical compound C=1C=CC=CC=1[C@]1(OC(=O)CC)CCN(C)C[C@@H]1C UVAZQQHAVMNMHE-BBRMVZONSA-N 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 229960000669 acetylleucine Drugs 0.000 description 1
• 229960001138 acetylsalicylic acid Drugs 0.000 description 1
• 239000002253 acid Substances 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 229930183665 actinomycin Natural products 0.000 description 1
• RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
• 230000006536 aerobic glycolysis Effects 0.000 description 1
• 229960001391 alfentanil Drugs 0.000 description 1
• 229960003687 alizapride Drugs 0.000 description 1
• 229930013930 alkaloid Natural products 0.000 description 1
• 229940100198 alkylating agent Drugs 0.000 description 1
• 239000002168 alkylating agent Substances 0.000 description 1
• 230000000172 allergic effect Effects 0.000 description 1
• 229960004538 alprazolam Drugs 0.000 description 1
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
• 229960000473 altretamine Drugs 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 238000000540 analysis of variance Methods 0.000 description 1
• 239000004037 angiogenesis inhibitor Substances 0.000 description 1
• 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 229940045799 anthracyclines and related substance Drugs 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000000844 anti-bacterial effect Effects 0.000 description 1
• 230000003432 anti-folate effect Effects 0.000 description 1
• 230000000340 anti-metabolite Effects 0.000 description 1
• 230000006023 anti-tumor response Effects 0.000 description 1
• 229940127074 antifolate Drugs 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 239000003429 antifungal agent Substances 0.000 description 1
• 229940100197 antimetabolite Drugs 0.000 description 1
• 239000002256 antimetabolite Substances 0.000 description 1
• 239000003080 antimitotic agent Substances 0.000 description 1
• VEQOALNAAJBPNY-UHFFFAOYSA-N antipyrine Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 description 1
• 230000005975 antitumor immune response Effects 0.000 description 1
• 201000011165 anus cancer Diseases 0.000 description 1
• VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
• 229960004046 apomorphine Drugs 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 125000003118 aryl group Chemical group 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 229940009098 aspartate Drugs 0.000 description 1
• 208000010668 atopic eczema Diseases 0.000 description 1
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
• 229950005951 azasetron Drugs 0.000 description 1
• 230000001580 bacterial effect Effects 0.000 description 1
• 229940049706 benzodiazepine Drugs 0.000 description 1
• 150000001557 benzodiazepines Chemical class 0.000 description 1
• 229960004564 benzquinamide Drugs 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 229950000011 betaprodine Drugs 0.000 description 1
• 230000008436 biogenesis Effects 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 210000004369 blood Anatomy 0.000 description 1
• 239000008280 blood Substances 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 238000002725 brachytherapy Methods 0.000 description 1
• 210000000481 breast Anatomy 0.000 description 1
• 229960001034 bromopride Drugs 0.000 description 1
• MOYGZHXDRJNJEP-UHFFFAOYSA-N buclizine Chemical compound C1=CC(C(C)(C)C)=CC=C1CN1CCN(C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1 MOYGZHXDRJNJEP-UHFFFAOYSA-N 0.000 description 1
• 229960001705 buclizine Drugs 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
• 229960001736 buprenorphine Drugs 0.000 description 1
• QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
• 229960002495 buspirone Drugs 0.000 description 1
• 238000010805 cDNA synthesis kit Methods 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• 229960004117 capecitabine Drugs 0.000 description 1
• 229960004562 carboplatin Drugs 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 229960005243 carmustine Drugs 0.000 description 1
• 229960000590 celecoxib Drugs 0.000 description 1
• RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 201000010881 cervical cancer Diseases 0.000 description 1
• UKTAZPQNNNJVKR-KJGYPYNMSA-N chembl2368925 Chemical compound C1=CC=C2C(C(O[C@@H]3C[C@@H]4C[C@H]5C[C@@H](N4CC5=O)C3)=O)=CNC2=C1 UKTAZPQNNNJVKR-KJGYPYNMSA-N 0.000 description 1
• 238000006243 chemical reaction Methods 0.000 description 1
• 108700010039 chimeric receptor Proteins 0.000 description 1
• 229960004782 chlordiazepoxide Drugs 0.000 description 1
• ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
• 229960004926 chlorobutanol Drugs 0.000 description 1
• ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
• 229960001076 chlorpromazine Drugs 0.000 description 1
• 230000007665 chronic toxicity Effects 0.000 description 1
• 231100000160 chronic toxicity Toxicity 0.000 description 1
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
• 229960004316 cisplatin Drugs 0.000 description 1
• 229960001791 clebopride Drugs 0.000 description 1
• DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
• 229960003120 clonazepam Drugs 0.000 description 1
• 238000010367 cloning Methods 0.000 description 1
• 229960004362 clorazepate Drugs 0.000 description 1
• XDDJGVMJFWAHJX-UHFFFAOYSA-M clorazepic acid anion Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(C(=O)[O-])N=C1C1=CC=CC=C1 XDDJGVMJFWAHJX-UHFFFAOYSA-M 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 208000029742 colonic neoplasm Diseases 0.000 description 1
• 239000012141 concentrate Substances 0.000 description 1
• 230000004940 costimulation Effects 0.000 description 1
• 230000000139 costimulatory effect Effects 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
• 229950002213 cyclazocine Drugs 0.000 description 1
• 229960003564 cyclizine Drugs 0.000 description 1
• UVKZSORBKUEBAZ-UHFFFAOYSA-N cyclizine Chemical compound C1CN(C)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 UVKZSORBKUEBAZ-UHFFFAOYSA-N 0.000 description 1
• 229960004397 cyclophosphamide Drugs 0.000 description 1
• 229960000684 cytarabine Drugs 0.000 description 1
• 230000016396 cytokine production Effects 0.000 description 1
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
• 238000002784 cytotoxicity assay Methods 0.000 description 1
• 231100000263 cytotoxicity test Toxicity 0.000 description 1
• 229960003901 dacarbazine Drugs 0.000 description 1
• 229960000640 dactinomycin Drugs 0.000 description 1
• 229960000975 daunorubicin Drugs 0.000 description 1
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 229960001985 dextromethorphan Drugs 0.000 description 1
• XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 1
• 229960004193 dextropropoxyphene Drugs 0.000 description 1
• 239000010432 diamond Substances 0.000 description 1
• 229960002069 diamorphine Drugs 0.000 description 1
• 229960003529 diazepam Drugs 0.000 description 1
• AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
• 229960001259 diclofenac Drugs 0.000 description 1
• DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• 229960000616 diflunisal Drugs 0.000 description 1
• HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 1
• UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
• 229960004993 dimenhydrinate Drugs 0.000 description 1
• OGAKLTJNUQRZJU-UHFFFAOYSA-N diphenidol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(O)CCCN1CCCCC1 OGAKLTJNUQRZJU-UHFFFAOYSA-N 0.000 description 1
• 229960003520 diphenidol Drugs 0.000 description 1
• HYPPXZBJBPSRLK-UHFFFAOYSA-N diphenoxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 1
• 229960004192 diphenoxylate Drugs 0.000 description 1
• 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
• BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
• 229910000397 disodium phosphate Inorganic materials 0.000 description 1
• 235000019800 disodium phosphate Nutrition 0.000 description 1
• 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
• 229960003668 docetaxel Drugs 0.000 description 1
• 229960003413 dolasetron Drugs 0.000 description 1
• 229960001253 domperidone Drugs 0.000 description 1
• FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 230000003828 downregulation Effects 0.000 description 1
• 239000002158 endotoxin Substances 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 229940088598 enzyme Drugs 0.000 description 1
• 229960001904 epirubicin Drugs 0.000 description 1
• SIHZWGODIRRSRA-ONEGZZNKSA-N erbstatin Chemical compound OC1=CC=C(O)C(\C=C\NC=O)=C1 SIHZWGODIRRSRA-ONEGZZNKSA-N 0.000 description 1
• 210000003743 erythrocyte Anatomy 0.000 description 1
• 239000003797 essential amino acid Substances 0.000 description 1
• 235000020776 essential amino acid Nutrition 0.000 description 1
• FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
• 229960001842 estramustine Drugs 0.000 description 1
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
• WGJHHMKQBWSQIY-UHFFFAOYSA-N ethoheptazine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCCN(C)CC1 WGJHHMKQBWSQIY-UHFFFAOYSA-N 0.000 description 1
• 229960000569 ethoheptazine Drugs 0.000 description 1
• 229960005293 etodolac Drugs 0.000 description 1
• XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
• 229960005420 etoposide Drugs 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 229960001419 fenoprofen Drugs 0.000 description 1
• 229960002428 fentanyl Drugs 0.000 description 1
• PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
• 239000012091 fetal bovine serum Substances 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 229960000390 fludarabine Drugs 0.000 description 1
• GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 229960002390 flurbiprofen Drugs 0.000 description 1
• SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
• 239000004052 folic acid antagonist Substances 0.000 description 1
• VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
• 235000008191 folinic acid Nutrition 0.000 description 1
• 239000011672 folinic acid Substances 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 239000012458 free base Substances 0.000 description 1
• 238000004108 freeze drying Methods 0.000 description 1
• 230000005714 functional activity Effects 0.000 description 1
• 238000010230 functional analysis Methods 0.000 description 1
• 102000037865 fusion proteins Human genes 0.000 description 1
• 108020001507 fusion proteins Proteins 0.000 description 1
• 201000010175 gallbladder cancer Diseases 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
• 229960005277 gemcitabine Drugs 0.000 description 1
• 229940045109 genistein Drugs 0.000 description 1
• TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
• 235000006539 genistein Nutrition 0.000 description 1
• ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 229930195712 glutamate Natural products 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 230000034659 glycolysis Effects 0.000 description 1
• 210000003714 granulocyte Anatomy 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 239000001963 growth medium Substances 0.000 description 1
• 210000002443 helper t lymphocyte Anatomy 0.000 description 1
• MCAHMSDENAOJFZ-BVXDHVRPSA-N herbimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](OC)[C@@H](OC)C[C@H](C)[C@@H](OC)C2=CC(=O)C=C1C2=O MCAHMSDENAOJFZ-BVXDHVRPSA-N 0.000 description 1
• UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 230000003118 histopathologic effect Effects 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 230000005745 host immune response Effects 0.000 description 1
• 102000055277 human IL2 Human genes 0.000 description 1
• 235000011167 hydrochloric acid Nutrition 0.000 description 1
• LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 1
• 229960000240 hydrocodone Drugs 0.000 description 1
• OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
• 239000001257 hydrogen Substances 0.000 description 1
• 229910052739 hydrogen Inorganic materials 0.000 description 1
• WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
• 229960001410 hydromorphone Drugs 0.000 description 1
• 125000001165 hydrophobic group Chemical group 0.000 description 1
• 150000004679 hydroxides Chemical class 0.000 description 1
• 229960000930 hydroxyzine Drugs 0.000 description 1
• ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 1
• 229960001680 ibuprofen Drugs 0.000 description 1
• 229960000908 idarubicin Drugs 0.000 description 1
• 229960001101 ifosfamide Drugs 0.000 description 1
• HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
• 229960003685 imatinib mesylate Drugs 0.000 description 1
• YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 1
• 230000005934 immune activation Effects 0.000 description 1
• 230000006450 immune cell response Effects 0.000 description 1
• 210000000987 immune system Anatomy 0.000 description 1
• 230000000899 immune system response Effects 0.000 description 1
• 230000006028 immune-suppresssive effect Effects 0.000 description 1
• 238000011575 immunodeficient mouse model Methods 0.000 description 1
• 230000003308 immunostimulating effect Effects 0.000 description 1
• 230000002779 inactivation Effects 0.000 description 1
• 229960000905 indomethacin Drugs 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 239000007972 injectable composition Substances 0.000 description 1
• 150000007529 inorganic bases Chemical class 0.000 description 1
• 230000010354 integration Effects 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 230000004068 intracellular signaling Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 229960004768 irinotecan Drugs 0.000 description 1
• UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
• 229960000310 isoleucine Drugs 0.000 description 1
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
• IFKPLJWIEQBPGG-UHFFFAOYSA-N isomethadone Chemical compound C=1C=CC=CC=1C(C(C)CN(C)C)(C(=O)CC)C1=CC=CC=C1 IFKPLJWIEQBPGG-UHFFFAOYSA-N 0.000 description 1
• 229950009272 isomethadone Drugs 0.000 description 1
• 230000006122 isoprenylation Effects 0.000 description 1
• JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
• 239000007951 isotonicity adjuster Substances 0.000 description 1
• DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
• 229960000991 ketoprofen Drugs 0.000 description 1
• 229960004752 ketorolac Drugs 0.000 description 1
• OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
• 201000010982 kidney cancer Diseases 0.000 description 1
• 229940043355 kinase inhibitor Drugs 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 229960001691 leucovorin Drugs 0.000 description 1
• 229960001614 levamisole Drugs 0.000 description 1
• 229960003406 levorphanol Drugs 0.000 description 1
• 108020001756 ligand binding domains Proteins 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 201000007270 liver cancer Diseases 0.000 description 1
• 210000005229 liver cell Anatomy 0.000 description 1
• 208000014018 liver neoplasm Diseases 0.000 description 1
• 238000001325 log-rank test Methods 0.000 description 1
• 229960002247 lomustine Drugs 0.000 description 1
• 229960001571 loperamide Drugs 0.000 description 1
• RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 1
• 229960004391 lorazepam Drugs 0.000 description 1
• 201000005202 lung cancer Diseases 0.000 description 1
• 210000005265 lung cell Anatomy 0.000 description 1
• 208000020816 lung neoplasm Diseases 0.000 description 1
• 210000004698 lymphocyte Anatomy 0.000 description 1
• 210000003563 lymphoid tissue Anatomy 0.000 description 1
• 239000012139 lysis buffer Substances 0.000 description 1
• 229910001629 magnesium chloride Inorganic materials 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 229940013798 meclofenamate Drugs 0.000 description 1
• 229960001474 meclozine Drugs 0.000 description 1
• 229960003464 mefenamic acid Drugs 0.000 description 1
• HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
• 229960001428 mercaptopurine Drugs 0.000 description 1
• 108020004999 messenger RNA Proteins 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 230000037353 metabolic pathway Effects 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 230000001394 metastastic effect Effects 0.000 description 1
• 208000037819 metastatic cancer Diseases 0.000 description 1
• 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
• 206010061289 metastatic neoplasm Diseases 0.000 description 1
• 229960001797 methadone Drugs 0.000 description 1
• XMQICEWOKPEQRG-UHFFFAOYSA-N methallatal Chemical compound CC(=C)CC1(CC)C(=O)NC(=S)NC1=O XMQICEWOKPEQRG-UHFFFAOYSA-N 0.000 description 1
• 229950010373 methallatal Drugs 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• 229960004503 metoclopramide Drugs 0.000 description 1
• TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
• BQDBKDMTIJBJLA-UHFFFAOYSA-N metopimazine Chemical compound C12=CC(S(=O)(=O)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCC(C(N)=O)CC1 BQDBKDMTIJBJLA-UHFFFAOYSA-N 0.000 description 1
• 229960000767 metopimazine Drugs 0.000 description 1
• NPZXCTIHHUUEEJ-CMKMFDCUSA-N metopon Chemical compound O([C@@]1(C)C(=O)CC[C@@H]23)C4=C5[C@@]13CCN(C)[C@@H]2CC5=CC=C4O NPZXCTIHHUUEEJ-CMKMFDCUSA-N 0.000 description 1
• 229950006080 metopon Drugs 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
• 210000003470 mitochondria Anatomy 0.000 description 1
• 229960004857 mitomycin Drugs 0.000 description 1
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
• 229960001156 mitoxantrone Drugs 0.000 description 1
• 239000002991 molded plastic Substances 0.000 description 1
• 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
• 235000019799 monosodium phosphate Nutrition 0.000 description 1
• 229960005181 morphine Drugs 0.000 description 1
• 229960002967 nabilone Drugs 0.000 description 1
• GECBBEABIDMGGL-RTBURBONSA-N nabilone Chemical compound C1C(=O)CC[C@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@@H]21 GECBBEABIDMGGL-RTBURBONSA-N 0.000 description 1
• 229960004270 nabumetone Drugs 0.000 description 1
• 229960002009 naproxen Drugs 0.000 description 1
• CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
• 210000000581 natural killer T-cell Anatomy 0.000 description 1
• 230000012177 negative regulation of immune response Effects 0.000 description 1
• 229960005419 nitrogen Drugs 0.000 description 1
• 229910052757 nitrogen Inorganic materials 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 102000039446 nucleic acids Human genes 0.000 description 1
• 108020004707 nucleic acids Proteins 0.000 description 1
• 239000002773 nucleotide Substances 0.000 description 1
• 125000003729 nucleotide group Chemical group 0.000 description 1
• 231100000590 oncogenic Toxicity 0.000 description 1
• 230000002246 oncogenic effect Effects 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 229960001756 oxaliplatin Drugs 0.000 description 1
• DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 229960002085 oxycodone Drugs 0.000 description 1
• 229960005118 oxymorphone Drugs 0.000 description 1
• 229960001592 paclitaxel Drugs 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• 229940049954 penicillin Drugs 0.000 description 1
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
• 229960000482 pethidine Drugs 0.000 description 1
• 239000000546 pharmaceutical excipient Substances 0.000 description 1
• 229960005222 phenazone Drugs 0.000 description 1
• 229960003742 phenol Drugs 0.000 description 1
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
• 235000011007 phosphoric acid Nutrition 0.000 description 1
• 150000003016 phosphoric acids Chemical class 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
• 238000002428 photodynamic therapy Methods 0.000 description 1
• 239000003504 photosensitizing agent Substances 0.000 description 1
• OSJJYEUEJRVVOD-UHFFFAOYSA-N pipamazine Chemical compound C1CC(C(=O)N)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 OSJJYEUEJRVVOD-UHFFFAOYSA-N 0.000 description 1
• 229950008580 pipamazine Drugs 0.000 description 1
• 229960002702 piroxicam Drugs 0.000 description 1
• QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
• 150000003057 platinum Chemical class 0.000 description 1
• 229960003171 plicamycin Drugs 0.000 description 1
• 229920000656 polylysine Polymers 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 239000011736 potassium bicarbonate Substances 0.000 description 1
• 235000015497 potassium bicarbonate Nutrition 0.000 description 1
• 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
• 239000001103 potassium chloride Substances 0.000 description 1
• WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Inorganic materials [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
• TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
• 244000144977 poultry Species 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
• 229960000624 procarbazine Drugs 0.000 description 1
• 229960003111 prochlorperazine Drugs 0.000 description 1
• WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• 229960003910 promethazine Drugs 0.000 description 1
• 108060006633 protein kinase Proteins 0.000 description 1
• 150000003212 purines Chemical class 0.000 description 1
• 150000003230 pyrimidines Chemical class 0.000 description 1
• 238000011362 radionuclide therapy Methods 0.000 description 1
• 108700015048 receptor decoy activity proteins Proteins 0.000 description 1
• 210000003289 regulatory T cell Anatomy 0.000 description 1
• 229960003394 remifentanil Drugs 0.000 description 1
• 230000003362 replicative effect Effects 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 108091008146 restriction endonucleases Proteins 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 229960000371 rofecoxib Drugs 0.000 description 1
• RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
• 239000000523 sample Substances 0.000 description 1
• 229960002646 scopolamine Drugs 0.000 description 1
• STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
• 238000012163 sequencing technique Methods 0.000 description 1
• 210000002966 serum Anatomy 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 230000009131 signaling function Effects 0.000 description 1
• 201000000849 skin cancer Diseases 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 229940075582 sorbic acid Drugs 0.000 description 1
• 235000010199 sorbic acid Nutrition 0.000 description 1
• 239000004334 sorbic acid Substances 0.000 description 1
• 230000009870 specific binding Effects 0.000 description 1
• 201000002471 spleen cancer Diseases 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 229960005322 streptomycin Drugs 0.000 description 1
• 239000000126 substance Substances 0.000 description 1
• GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 description 1
• 229960004739 sufentanil Drugs 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
• 229960000894 sulindac Drugs 0.000 description 1
• 229960004940 sulpiride Drugs 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
• NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
• 229960001278 teniposide Drugs 0.000 description 1
• 201000003120 testicular cancer Diseases 0.000 description 1
• 229930101283 tetracycline Natural products 0.000 description 1
• 229960002180 tetracycline Drugs 0.000 description 1
• 235000019364 tetracycline Nutrition 0.000 description 1
• 150000003522 tetracyclines Chemical class 0.000 description 1
• 229960004869 thiethylperazine Drugs 0.000 description 1
• XCTYLCDETUVOIP-UHFFFAOYSA-N thiethylperazine Chemical compound C12=CC(SCC)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(C)CC1 XCTYLCDETUVOIP-UHFFFAOYSA-N 0.000 description 1
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
• 229940033663 thimerosal Drugs 0.000 description 1
• 229960003397 thioproperazine Drugs 0.000 description 1
• VZYCZNZBPPHOFY-UHFFFAOYSA-N thioproperazine Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(C)CC1 VZYCZNZBPPHOFY-UHFFFAOYSA-N 0.000 description 1
• 229960003087 tioguanine Drugs 0.000 description 1
• 229960003989 tocilizumab Drugs 0.000 description 1
• 229960000303 topotecan Drugs 0.000 description 1
• UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
• LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 1
• 230000026683 transduction Effects 0.000 description 1
• 238000010361 transduction Methods 0.000 description 1
• FEZBIKUBAYAZIU-UHFFFAOYSA-N trimethobenzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NCC=2C=CC(OCCN(C)C)=CC=2)=C1 FEZBIKUBAYAZIU-UHFFFAOYSA-N 0.000 description 1
• 229960004161 trimethobenzamide Drugs 0.000 description 1
• 229960003688 tropisetron Drugs 0.000 description 1
• UIVFDCIXTSJXBB-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C[C]2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CN=C21 UIVFDCIXTSJXBB-ITGUQSILSA-N 0.000 description 1
• 230000004614 tumor growth Effects 0.000 description 1
• 230000005909 tumor killing Effects 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
• 241000701161 unidentified adenovirus Species 0.000 description 1
• 241001529453 unidentified herpesvirus Species 0.000 description 1
• 241001430294 unidentified retrovirus Species 0.000 description 1
• 238000002255 vaccination Methods 0.000 description 1
• 238000001291 vacuum drying Methods 0.000 description 1
• 235000013311 vegetables Nutrition 0.000 description 1
• 108700026220 vif Genes Proteins 0.000 description 1
• 229960003048 vinblastine Drugs 0.000 description 1
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
• 229960004528 vincristine Drugs 0.000 description 1
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
• 229960004355 vindesine Drugs 0.000 description 1
• UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
• 229960002066 vinorelbine Drugs 0.000 description 1
• GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1